MEDication Focused Outpatient Care for Underutilization of Secondary Prevention

Korey Kennelty402 enrolled

Overview

The study tested whether a pharmacist-run cardiovascular risk service (CVRS) at the University of Iowa can increase use of national standards of care in clinics

This project conducted a multicenter, cluster-randomized study utilizing a centralized CVRS for medical offices with large geographic, racial and ethnic diversity to determine the extent to which the CVRS model will be implemented. Twenty primary care offices were randomized to either the CVRS arm or a usual care arm, and 18 continued in the study. Each clinic enrolled 20-30 patients per office for a total of 402 subjects, of which 186 represented racial minorities. Subjects in the intervention arm clinic had regular contact by phone, email or text with a CVRS clinical pharmacist housed at the University of Iowa. The pharmacist communicated with the subject, with the site clinical pharmacist and, as needed, with the site provider to optimize both the subject's pharmaceutical regimen and lifestyle behaviors. The CVRS intervention lasted for 12 months. A complex algorithm was used to calculate the degree to which the subject's care and medical regimen follows national guidelines for reducing the risk of developing cardiovascular risk. Post-intervention telephone interviews are being conducted with 20 intervention subjects in order to assess their experience with the intervention and barriers and facilitators to the intervention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

402

Conditions

Diabetes Hyperlipidemia Hypertension Cardiovascular Disease

Interventions

CVRS InterventionBEHAVIORAL

A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.

Eligibility

Sex: ALLMin age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * English speakers age 55 or greater * Must have a medical history of at least one of the following: * Coronary artery disease * Myocardial infarction * Stroke * Transient Ischemic Attack * Atrial Fibrillation * Systolic heart failure * Peripheral vascular disease/claudication * Carotid artery disease * Diabetes with either: Low density lipoprotein (LDL) 100 or greater AND/OR systolic blood pressure 140 or higher or diastolic blood pressure 90 or higher Exclusion Criteria: * Signs of acute angina, stroke, heart failure or renal failure * Systolic blood pressure 200 or greater or diastolic blood pressure 115 or greater * Significant hepatic disease, including: Cirrhosis, Hepatitis B or C infection, Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) 3 times control or higher, or total bilirubin 2.0 mg/dl or higher

Locations (18)

University of Florida

Gainesville, Florida, United States

University of South Florida

Tampa, Florida, United States

Outcomes

Primary Outcomes

The mean percent of applicable Guideline Advantage standards of care that are met at 12 months

Of the 53 specific standards of care listed in the Guideline Advantage criteria, the mean percent of those standards applicable to each subject that are met at the 12 month time point

Time frame: 12 months

Secondary Outcomes

The average cost per subject, measured in dollars and cents, of implementing the intervention

The cost per subject will include costs for visits to the primary care physician, the cost of prescribed drugs, and the cost for the time spent by study pharmacists communicating with the patient, creating a care plan, and communicating with the patient's primary care provider.

Time frame: 12 months

The percent of intervention group patients who rate the intervention as helpful (versus not helpful)

Of the subset of 20 intervention group patients who are interviewed about the study intervention, the percent who state that the intervention was helpful (versus not helpful).

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.